Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Insulet Corporation (NASDAQ:PODD)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Insulet stock on October 20th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

Insulet Price Performance

NASDAQ PODD traded down $0.74 on Thursday, hitting $149.29. The stock had a trading volume of 745,601 shares, compared to its average volume of 1,400,559. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51. The company has a market capitalization of $10.36 billion, a price-to-earnings ratio of 24.31, a price-to-earnings-growth ratio of 1.14 and a beta of 1.06. The firm has a 50-day moving average of $142.11 and a 200-day moving average of $174.10.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.59 by $0.40. The firm had revenue of $842.00 million during the quarter, compared to analyst estimates of $832.63 million. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The business’s revenue for the quarter was up 19.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.24 EPS. Equities analysts expect that Insulet Corporation will post 6.76 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PODD shares. Benchmark dropped their price objective on shares of Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Robert W. Baird set a $175.00 target price on Insulet in a research note on Thursday, August 6th. Canaccord Genuity Group lowered their price target on Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. UBS Group raised their price target on Insulet from $150.00 to $171.00 and gave the company a “neutral” rating in a research report on Thursday, November 5th. Finally, Stifel Nicolaus dropped their price target on Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Twelve equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $185.67.

Hedge Funds Weigh In On Insulet

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Allworth Financial LP raised its position in shares of Insulet by 2.3% in the 3rd quarter. Allworth Financial LP now owns 3,104 shares of the medical instruments supplier’s stock worth $405,000 after acquiring an additional 71 shares in the last quarter. State of Wyoming boosted its position in shares of Insulet by 34.6% during the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after purchasing an additional 73 shares in the last quarter. American Trust grew its stake in Insulet by 8.6% in the first quarter. American Trust now owns 1,180 shares of the medical instruments supplier’s stock worth $248,000 after purchasing an additional 93 shares during the period. Basecamp Wealth Advisors LLC grew its stake in Insulet by 48.3% in the first quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 102 shares during the period. Finally, Elevation Wealth Partners LLC grew its stake in Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 104 shares during the period.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Insulet

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.